Company Overview of Aspreva International Ltd.
Aspreva International Ltd. identifies, develops, and commercializes approved drugs and drug candidates for new indications. It evaluates and develops CellCept, an orally delivered immunosuppressant agent, in the treatment of the autoimmune diseases such as lupus nephritis and pemphigus vulgaris. The company operates in the United States, Canada, Switzerland, and the United Kingdom. The company was formerly known as Galenica Canada Ltd. The company was founded in 2001 and is based in Victoria, Canada. Aspreva International Ltd. operates as a subsidiary of Vifor Pharma Ltd.
1203–4464 Markham Street
Victoria, BC V8Z 7X8
Founded in 2001
Key Executives for Aspreva International Ltd.
Similar Private Companies By Industry
|1127466 B.C. Ltd.||Americas|
|9037136 Canada Inc.||Americas|
|AAA Heidelberg Inc.||Americas|
|Ab Biotech Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Aspreva International Ltd., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.